Sirona Capital
Overview
Sirona Capital invests in the future of healthcare innovation and therapeutics. As a dedicated healthcare venture capital fund, they are committed to identifying and supporting visionary entrepreneurs who are reshaping the landscape of healthcare and life sciences . Their mission is to advance pioneering companies that continue to push the boundaries of medical technology, biopharmaceuticals and more .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Kailera Therapeutics | Oct 2025 | Series B | Co-investor |
| ARVION | Apr 2018 | Series C | Co-investor |
| CG Oncology | Nov 2022 | Series E | - |
| ArriVent | Mar 2023 | Series B | Co-investor |
| Synnovation Therapeutics | Jan 2024 | Series A | Co-investor |
For institutional investors. Book with your work email.
Key People
Ting Feng
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Sirona Capital based?
Sirona Capital is headquartered in Cayman Islands.
When was Sirona Capital founded?
Sirona Capital was founded in 2021.
How many portfolio companies does Sirona Capital have?
Sirona Capital has 10 portfolio companies in Caplight's dataset.
What are some companies in Sirona Capital's portfolio?
Portfolio companies visible on Caplight include Kailera Therapeutics, ARVION, CG Oncology, ArriVent, Synnovation Therapeutics.
What was Sirona Capital's most recent investment shown here?
Sirona Capital's most recent investment in this portfolio sample was in Kailera Therapeutics in 2025.
What sectors does Sirona Capital focus on?
Sirona Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Cybersecurity, Enterprise Software.
What company stages does Sirona Capital focus on?
Sirona Capital typically invests at the Mid stage.
What is Sirona Capital's AUM?
Sirona Capital's assets under management are estimated between $50.0M and $100.0M.